Develops cancer therapies aimed at improving patient outcomes, with a focus on immune-oncology and targeted cancer treatments.
BeyondSpring Inc., a clinical-stage biopharmaceutical company, along with its subsidiaries, is dedicated to developing innovative cancer therapies. The company's flagship product, Plinabulin, is a selective immune-modulating microtubule-binding agent. Plinabulin has successfully completed Phase III clinical trials for preventing chemotherapy-induced neutropenia and treating later-stage non-small cell lung cancer (NSCLC).
In addition to its primary uses, Plinabulin is being explored in combination with various immuno-oncology agents. These include nivolumab, a PD-1 antibody for NSCLC treatment, and a combination of nivolumab and ipilimumab, a CTLA-4 antibody for small cell lung cancer (SCLC). BeyondSpring is also investigating the use of Plinabulin in conjunction with PD-1 or PD-L1 antibodies and radiation therapy for treating multiple cancer types, highlighting its versatility and potential in oncology.
Founded in 2010 and headquartered in New York, New York, BeyondSpring is also advancing three small molecule immune agents currently in preclinical stages and developing a comprehensive drug development platform. Throught its innovative research and development efforts, BeyondSpring aims to offer new and effective treatment options for cancer patients worldwide, pushing the boundaries of current cancer therapy paradigms.